Journal: Journal of Lipid Research

Article Title: Prevention of TGFβ induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr−/− mice

doi: 10.1194/jlr.p040139

Figure Lengend Snippet: Fig. 3. TGF neutralizing antibody 1D11 attenuates biglycan accumulation and biglycan-apoB colocalization in atherosclerotic lesions. Sections of aortic sinus were double stained for both apoB (green) and one of the proteoglycans [biglycan (BGN): (A–D); perlecan (PLN): (E–H); and decorin (DCN): (J–M), all red] by immunofl uorescence analysis and photos were taken using confocal microscopy. Nuclei were stained by DAPI (blue). Yellow demonstrates colocalization between apoB and each of the three proteoglycans. In each photo, the lumen is on the upper left side of the image. Photos shown are representative for 3–4 mice per group (group indicated at the top of each column of photos) magnifi ed 630×. Biglycan (N) and perlecan (P) immunostained areas were quantifi ed using ImageJ software. All analyses were done by two-way ANOVA with pair-wise comparisons. * P < 0.05.

Article Snippet: Equal amounts of protein were treated with chondroitinase or heparinase III to remove GAG, then separated by SDS-PAGE using 8% gels (biglycan molecular mass 42 kDa; perlecan molecular mass 400 kDa) followed by immunoprobing with an anti-biglycan antibody (R and D Systems) or anti-perlecan antibody (Accurate Chemical, Westbury, NY).

Techniques: Staining, Confocal Microscopy, Software

Journal: Journal of Lipid Research

Article Title: Prevention of TGFβ induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr−/− mice

doi: 10.1194/jlr.p040139

Figure Lengend Snippet: Fig. 4. TGF neutralizing antibody 1D11 attenuates biglycan accumulation in atherosclerotic carotids. Carotid arteries were collected at the end of the atherosclerosis studies and protein extracted and immuno- blotted for biglycan (A) or perlecan (C); actin is shown as the loading control. Densitometry quantifi cation was performed on blots (B) biglycan and (D) perlecan. Shown are means ± SEM from n = 2–4 mice per group. All analyses were done by two-way ANOVA with pair-wise comparisons. * P < 0.05.

Article Snippet: Equal amounts of protein were treated with chondroitinase or heparinase III to remove GAG, then separated by SDS-PAGE using 8% gels (biglycan molecular mass 42 kDa; perlecan molecular mass 400 kDa) followed by immunoprobing with an anti-biglycan antibody (R and D Systems) or anti-perlecan antibody (Accurate Chemical, Westbury, NY).

Techniques: Control